A citation-based method for searching scientific literature

Stephen Tyring, Alice Gottlieb, Kim Papp, Ken Gordon, Craig Leonardi, Andrea Wang, Deepa Lalla, Michael Woolley, Angelika Jahreis, Ralph Zitnik, David Cella, Ranga Krishnan. Lancet 2006
Times Cited: 726







List of co-cited articles
1304 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.
C L Raison, R Dantzer, K W Kelley, M A Lawson, B J Woolwine, G Vogt, J R Spivey, K Saito, A H Miller. Mol Psychiatry 2010
407
6

Psoriasis.
Wolf-Henning Boehncke, Michael P Schön. Lancet 2015
933
6

Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).
Xuejun Zhu, Min Zheng, Michael Song, Yaung-Kaung Shen, Daphne Chan, Philippe O Szapary, Baoxi Wang. J Drugs Dermatol 2013
50
12



Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
P Rich, B Sigurgeirsson, D Thaci, J-P Ortonne, C Paul, R E Schopf, A Morita, K Roseau, E Harfst, A Guettner,[...]. Br J Dermatol 2013
179
6

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
127
6

Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Mamitaro Ohtsuki, Yukari Okubo, Mayumi Komine, Shinichi Imafuku, Robert M Day, Peng Chen, Rosemary Petric, Allan Maroli, Osamu Nemoto. J Dermatol 2017
30
20

The macrophage theory of depression.
R S Smith. Med Hypotheses 1991
607
6

Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy.
Paula Kopschina Feltes, Janine Doorduin, Hans C Klein, Luis Eduardo Juárez-Orozco, Rudi Ajo Dierckx, Cristina M Moriguchi-Jeckel, Erik Fj de Vries. J Psychopharmacol 2017
89
5

Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy.
Levent Sutcigil, Cagatay Oktenli, Ugur Musabak, Ali Bozkurt, Adnan Cansever, Ozcan Uzun, S Yavuz Sanisoglu, Zeki Yesilova, Nahit Ozmenler, Aytekin Ozsahin,[...]. Clin Dev Immunol 2007
220
5

Elevated IL-17 and TGF-β Serum Levels: A Positive Correlation between T-helper 17 Cell-Related Pro-Inflammatory Responses with Major Depressive Disorder.
Mohammad Hasan Davami, Rasoul Baharlou, Abbas Ahmadi Vasmehjani, Ahmad Ghanizadeh, Mitra Keshtkar, Iman Dezhkam, Mohammad Reza Atashzar. Basic Clin Neurosci 2016
58
8

Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.
Charles L Raison, Andrey S Borisov, Matthias Majer, Daniel F Drake, Giuseppe Pagnoni, Bobbi J Woolwine, Gerald J Vogt, Breanne Massung, Andrew H Miller. Biol Psychiatry 2009
237
5

Dose-dependent effects of endotoxin on neurobehavioral functions in humans.
Jan-Sebastian Grigoleit, Jennifer S Kullmann, Oliver T Wolf, Florian Hammes, Alexander Wegner, Stephanie Jablonowski, Harald Engler, Elke Gizewski, Reiner Oberbeck, Manfred Schedlowski. PLoS One 2011
133
5

Inflammatory T helper 17 cells promote depression-like behavior in mice.
Eléonore Beurel, Laurie E Harrington, Richard S Jope. Biol Psychiatry 2013
127
5

Cytokine, sickness behavior, and depression.
Robert Dantzer. Immunol Allergy Clin North Am 2009
402
5

Neuroimmune mechanisms of depression.
Georgia E Hodes, Veronika Kana, Caroline Menard, Miriam Merad, Scott J Russo. Nat Neurosci 2015
258
5

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Madhukar H Trivedi, A John Rush, Stephen R Wisniewski, Andrew A Nierenberg, Diane Warden, Louise Ritz, Grayson Norquist, Robert H Howland, Barry Lebowitz, Patrick J McGrath,[...]. Am J Psychiatry 2006
5

CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.
Vyara Valkanova, Klaus P Ebmeier, Charlotte L Allan. J Affect Disord 2013
475
5

Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.
D D Kiraly, S R Horn, N T Van Dam, S Costi, J Schwartz, S Kim-Schulze, M Patel, G E Hodes, S J Russo, M Merad,[...]. Transl Psychiatry 2017
79
6


The global burden of psoriatic skin disease.
K L Goff, C Karimkhani, L N Boyers, M A Weinstock, J P Lott, R J Hay, L E Coffeng, S A Norton, L Naldi, C Dunnick,[...]. Br J Dermatol 2015
52
9

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis.
Zarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, Lesley S Exton, M Firouz Mohd Mustapa, Eleanor Samarasekera, A David Burden, Ruth Murphy, Caroline M Owen, Richard Parslew,[...]. J Invest Dermatol 2017
77
6

Pathogenesis and clinical features of psoriasis.
Christopher Em Griffiths, Jonathan Nwn Barker. Lancet 2007
5


The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis.
Emmilia A Dowlatshahi, Marlies Wakkee, Lidia R Arends, Tamar Nijsten. J Invest Dermatol 2014
175
5

Depression and anxiety in psoriatic disease: prevalence and associated factors.
Emily McDonough, Renise Ayearst, Lihi Eder, Vinod Chandran, Cheryl F Rosen, Arane Thavaneswaran, Dafna D Gladman. J Rheumatol 2014
118
5

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Alexa B Kimball, Arielle G Bensimon, Annie Guerin, Andrew P Yu, Eric Q Wu, Martin M Okun, Yanjun Bao, Shiraz R Gupta, Parvez M Mulani. Am J Clin Dermatol 2011
36
13

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression.
Naomi R Wray, Stephan Ripke, Manuel Mattheisen, Maciej Trzaskowski, Enda M Byrne, Abdel Abdellaoui, Mark J Adams, Esben Agerbo, Tracy M Air, Till M F Andlauer,[...]. Nat Genet 2018
895
5

Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial.
Muhammad I Husain, Imran B Chaudhry, Nusrat Husain, Ameer B Khoso, Raza R Rahman, Munir M Hamirani, John Hodsoll, Inti Qurashi, John Fw Deakin, Allan H Young. J Psychopharmacol 2017
65
7

Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides.
Susana G Torres-Platas, Cristiana Cruceanu, Gary Gang Chen, Gustavo Turecki, Naguib Mechawar. Brain Behav Immun 2014
231
5

Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.
Jonathan Savitz, Wayne C Drevets, Brent E Wurfel, Bart N Ford, Patrick S F Bellgowan, Teresa A Victor, Jerzy Bodurka, T Kent Teague, Robert Dantzer. Brain Behav Immun 2015
111
5

Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide.
Johann Steiner, Hendrik Bielau, Ralf Brisch, Peter Danos, Oliver Ullrich, Christian Mawrin, Hans-Gert Bernstein, Bernhard Bogerts. J Psychiatr Res 2008
478
5

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
G G Krueger, R G Langley, A Y Finlay, C E M Griffiths, J M Woolley, D Lalla, A Jahreis. Br J Dermatol 2005
105
5

NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder.
Elísabet Alcocer-Gómez, Manuel de Miguel, Nieves Casas-Barquero, Jéssica Núñez-Vasco, José Antonio Sánchez-Alcazar, Ana Fernández-Rodríguez, Mario D Cordero. Brain Behav Immun 2014
211
5

Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress.
Georgia E Hodes, Madeline L Pfau, Marylene Leboeuf, Sam A Golden, Daniel J Christoffel, Dana Bregman, Nicole Rebusi, Mitra Heshmati, Hossein Aleyasin, Brandon L Warren,[...]. Proc Natl Acad Sci U S A 2014
343
5


Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept.
S Tyring, J Bagel, C Lynde, P Klekotka, E H Z Thompson, S R Gandra, Y Shi, G Kricorian. J Eur Acad Dermatol Venereol 2013
21
23

Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis.
Ignatios Ikonomidis, Evangelia Papadavid, George Makavos, Ioanna Andreadou, Maria Varoudi, Kostas Gravanis, Kostas Theodoropoulos, George Pavlidis, Helen Triantafyllidi, Paraskevi Moutsatsou,[...]. Circ Cardiovasc Imaging 2017
31
16

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study.
Robert Bissonnette, François Harel, James G Krueger, Marie-Claude Guertin, Malorie Chabot-Blanchet, Juana Gonzalez, Catherine Maari, Isabelle Delorme, Charles W Lynde, Jean-Claude Tardif. J Invest Dermatol 2017
47
10

Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis.
Saakshi Khattri, Orin Goldblum, Kathleen Solotkin, Yasmin Amir, Michelle S Min, Terri Ridenour, Fan Emily Yang, Mark Lebwohl. J Clin Aesthet Dermatol 2018
10
50

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
Craig Leonardi, Robert Matheson, Claus Zachariae, Gregory Cameron, Linda Li, Emily Edson-Heredia, Daniel Braun, Subhashis Banerjee. N Engl J Med 2012
687
5




Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Kim Papp, Jennifer C Cather, Les Rosoph, Howard Sofen, Richard G Langley, Robert T Matheson, ChiaChi Hu, Robert M Day. Lancet 2012
168
5


A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial).
Joel M Gelfand, Daniel B Shin, Abass Alavi, Drew A Torigian, Tom Werner, Maryte Papadopoulos, Junko Takeshita, Megan H Noe, Amit K Dey, Martin P Playford,[...]. J Invest Dermatol 2020
37
13

Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Linda Stein Gold, Jerry Bagel, Mark Lebwohl, J Mark Jackson, Rongdean Chen, Joana Goncalves, Eugenia Levi, Kristina Callis Duffin. J Drugs Dermatol 2018
22
22

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Carle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich. J Am Acad Dermatol 2019
42
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.